Wave Life Sciences [WVE] vs Capricor [CAPR] Detailed Stock Comparison

Wave Life Sciences Ltd.

NASDAQ
Loading...

Capricor Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Wave Life Sciences Ltd. wins in 9 metrics, Capricor Therapeutics Inc. wins in 6 metrics, with 1 ties. Wave Life Sciences Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Wave Life Sciences Ltd. Capricor Therapeutics Inc. Better
P/E Ratio (TTM) -5.93 -15.61 Wave Life Sciences Ltd.
Price-to-Book Ratio 2.60 6.62 Wave Life Sciences Ltd.
Debt-to-Equity Ratio 3.38 4.75 Wave Life Sciences Ltd.
PEG Ratio 0.02 -0.05 Wave Life Sciences Ltd.
EV/EBITDA -3.66 -16.23 Wave Life Sciences Ltd.
Profit Margin (TTM) 0.00% 0.00% Tie
Operating Margin (TTM) -327.44% 0.00% Capricor Therapeutics Inc.
Return on Equity -54.97% -46.56% Capricor Therapeutics Inc.
Return on Assets (TTM) -27.18% -25.68% Capricor Therapeutics Inc.
Free Cash Flow (TTM) $-188.21M $-81.54M Capricor Therapeutics Inc.
1-Year Return -15.54% 119.02% Capricor Therapeutics Inc.
Price-to-Sales Ratio (TTM) 31.64 N/A N/A
Enterprise Value $775.24M $1.72B Capricor Therapeutics Inc.
EV/Revenue Ratio 18.14 N/A N/A
Revenue per Share (TTM) $0 $0 Wave Life Sciences Ltd.
Earnings per Share (Diluted) $-1.19 $-2.26 Wave Life Sciences Ltd.
Beta (Stock Volatility) -1.32 0.48 Wave Life Sciences Ltd.
Short % of Float 9.00% 19.17% Wave Life Sciences Ltd.

Wave Life Sciences Ltd. vs Capricor Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

WVE
CAPR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Wave Life Sciences Ltd.2.21%5.26%-11.37%-51.65%-62.76%-62.38%
Capricor Therapeutics Inc.3.57%2.14%-7.19%-12.57%0.64%-5.62%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Wave Life Sciences Ltd.-15.54%47.49%-18.92%-69.63%-63.08%-63.08%
Capricor Therapeutics Inc.119.02%445.45%385.88%-42.15%-92.18%-98.04%

Performance & Financial Health Analysis: Wave Life Sciences Ltd. vs Capricor Therapeutics Inc.

MetricWVECAPR
Market Information
Market Cap i$1.35B$2.04B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i3,826,936987,380
90 Day Avg. Volume i5,712,9551,234,213
Last Close$6.00$26.72
52 Week Range$5.02 - $21.73$4.30 - $40.37
% from 52W High-72.39%-33.81%
All-Time High$56.00 (Sep 24, 2018)$3,500.00 (Oct 22, 2007)
% from All-Time High-89.29%-99.24%
Growth Metrics
Quarterly Revenue Growth-0.79%N/A
Quarterly Earnings GrowthN/A-1.00%
Financial Health
Profit Margin (TTM) i0.00%0.00%
Operating Margin (TTM) i-3.27%0.00%
Return on Equity (TTM) i-0.55%-0.47%
Debt to Equity (MRQ) i3.384.75
Cash & Liquidity
Book Value per Share (MRQ)$2.76$5.33
Cash per Share (MRQ)$3.20$5.53
Operating Cash Flow (TTM) i$-187,492,992$-69,811,264
Levered Free Cash Flow (TTM) i$-112,548,376$-39,600,748
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Wave Life Sciences Ltd. vs Capricor Therapeutics Inc.

MetricWVE (Apr 26, 2026)CAPR (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-5.93-15.61
Forward P/E i-5.36-56.73
PEG Ratio i0.02-0.05
Price to Sales (TTM) i31.64N/A
Price to Book (MRQ) i2.606.62
Market Capitalization
Market Capitalization i$1.35B$2.04B
Enterprise Value i$775.24M$1.72B
Enterprise Value Metrics
Enterprise to Revenue i18.14N/A
Enterprise to EBITDA i-3.66-16.23
Risk & Other Metrics
Beta i-1.320.48
Book Value per Share (MRQ) i$2.76$5.33

Financial Statements Comparison: Wave Life Sciences Ltd. vs Capricor Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricWVE (2025)CAPR (2025)
Revenue/Sales i42.73M0
Cost of Goods Sold iN/AN/A
COGS % of Revenue i0.0%-
Gross Profit iN/AN/A
Gross Margin i0.0%-
Research & Development i182.78M84.45M
Operating Income (EBIT) i-215.38M-108.14M
Operating Margin i-504.1%-
EBITDA i-217.01M-106.21M
EBITDA Margin i-507.9%-
Pre-Tax Income i-204.38M-105.04M
Pre-Tax Income % of Revenue i-478.3%-
Income Tax i01,600
Income Tax % of Revenue i0.0%-
Net Income (Profit) i-204.38M-105.04M
Profit Margin i-478.3%-

Balance Sheet & Liquidity Metrics

MetricWVE (2025)CAPR (2025)
Cash & Equivalents i602.07M287.85M
Total Current Assets i614.81M322.94M
Total Current Assets % of Revenue i1,438.9%-
Total Current Liabilities i95.07M35.84M
Total Current Liabilities % of Revenue i222.5%-
Long-Term Debt i9.41M14.32M
Long-Term Debt % of Revenue i22.0%-
Total Shareholders Equity i518.36M305.79M
Retained Earnings i-1.33B-304.88M
Retained Earnings % of Revenue i-3,104.0%-
Property, Plant & Equipment i12.46M22.27M

Cash Flow Statement Comparison

MetricWVE (2025)CAPR (2025)
Operating Cash Flow i-194.13M-71.86M
Operating Cash Flow % of Revenue i-454.3%-
Capital Expenditures i-718,000-11.72M
Free Cash Flow i-188.21M-81.54M
FCF Margin i-440.5%-
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricWVECAPR
Shares Short i13.21M10.04M
Short Ratio i2.247.73
Short % of Float i9.00%19.17%
Shares Outstanding i187.66M57.37M
Float Shares i124.17M48.61M
% Held by Insiders i14.21%9.47%
% Held by Institutions i93.84%53.91%
% Held by Public i-8.05%36.62%

Dividend Analysis & Yield Comparison: Wave Life Sciences Ltd. vs Capricor Therapeutics Inc.

MetricWVECAPR
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A